Bristol-Myers Squibb Company Ce (CELG-RI) Stock Analysis
Verdict: AVOID
CELG-RI is a high-risk tradeable contingent right down 41.4% in 90 days, offering binary payout dynamics against near-term total loss risk.
Investment score: 22/100
Analysis as of
Is Bristol-Myers Squibb Company Ce stock worth reviewing? AI model thesis
CELG-RI is a micro-cap tradeable contingent right ($143.60M market cap) priced at $0.0703. The model sees severe technical momentum deterioration (-41.4% over 90 days) and high binary risk of expiring worthless.
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 35/100 (weight 15%)
- Technical Momentum: 10/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 25/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
Bristol-Myers Squibb Company Ce opportunities and risks
What speaks for CELG-RI
- Binary Upside Potential
What speaks against CELG-RI
- Complete Capital Loss at Expiration
Frequently asked questions about Bristol-Myers Squibb Company Ce (CELG-RI)
Is CELG-RI stock a good investment?
The cached TradeMates AI model rates Bristol-Myers Squibb Company Ce as AVOID with an investment score of 22/100. CELG-RI is a micro-cap tradeable contingent right ($143.60M market cap) priced at $0.0703. The model sees severe technical momentum deterioration (-41.4% over 90 days) and high binary risk of expiring worthless. This is algorithmic model output, not personal investment advice.
Is CELG-RI stock a buy?
The TradeMates model verdict for CELG-RI is AVOID with an investment score of 22/100. Treat this as a model signal to review, not a personal buy recommendation.